// App-Quantinova.ai

557 : Genomic characteristics of breast cancer to predict response of neoadjuvant chemotherapy and long-term prognosis.

Researchers

Presenter

  • Ji-Yeon Kim

Principal Investigators

  • Kyunghee Park

  • Woong-Yang Park

  • Jeong Eon Lee

  • Seok Won Kim

  • Seok Jin Nam

  • Se-Kyung Lee

  • Zhengyan Kan

  • Yeon Hee Park

Medical Centers

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Samsung Genome Institute, Samsung Medical Center, Seoul, Korea

  • Samsung Medical Center, Seoul, Korea

  • The Division of Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

  • Seoul, South Korea

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • The Division of Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

  • Oncology Research and Development, Pfizer, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Tumor mutational burden

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Trastuzumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT02591966

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved